Skip to content
Clinical Trials – home

Autism spectrum disorder Diagnostics

13 / 15 trials open to patients12 countries

In short

Autism spectrum disorder is a condition that affects how people communicate and interact with the world around them. Recognizing the signs early and seeking proper assessment can open doors to support services that help individuals reach their full potential throughout their lives.

Key points

  • Early identification of autism, ideally during infancy or toddlerhood, significantly improves long-term outcomes through access to intervention services during critical developmental periods.
  • Autism diagnosis requires comprehensive evaluation by specialized professionals and cannot be confirmed through blood tests, brain scans, or any single medical procedure.
  • All children should be screened specifically for autism at their 18-month and 24-month well-child visits, in addition to general developmental monitoring.
  • The diagnostic process involves observing behavior, interviewing caregivers about developmental history, using standardized assessment tools, and testing speech, language, and hearing abilities.
  • Autism appears very differently across individuals, ranging from those who need significant daily support to those who live independently, making personalized evaluation essential.
  • Parents should begin early intervention services as soon as concerns arise, without waiting for a formal diagnostic confirmation, as early support leads to better outcomes.
  • Clinical trials require standardized diagnostic confirmation and functional assessments to ensure participants meet study criteria and to measure treatment effects accurately.
  • Many individuals, especially women and people from marginalized communities, remain undiagnosed throughout their lives due to diagnostic criteria that were historically based on specific populations.

Introduction: Who Should Undergo Diagnostics

Parents, caregivers, and healthcare providers should seek diagnostic evaluation for a child as soon as they notice signs or symptoms that suggest autism spectrum disorder. Early identification makes a significant difference because it allows children to access intervention services during critical developmental periods, when the brain is most responsive to learning and change.

Some children show signs of autism within their first year of life, while others may develop typically until around 18 to 24 months of age and then begin to lose skills they once had or stop gaining new ones. Any child who shows difficulties with social communication, delayed language development, repetitive behaviors, or unusual responses to sensory experiences should be evaluated, even if these signs seem mild at first.

Healthcare providers should monitor children's development at every well-child checkup. If there are any concerns about how a child is communicating, playing, learning, or behaving, a referral for specialized evaluation is appropriate. Parents do not need to wait for severe symptoms to appear before seeking help. Acting early can lead to better outcomes, as intervention services during the preschool years can make a significant difference in a child's development.

Autism can be diagnosed at any age, and some individuals are not identified until adolescence or adulthood. Teenagers and adults who have struggled with social relationships, experienced difficulty understanding unwritten social rules, or felt different from their peers may benefit from evaluation. A diagnosis later in life can help explain lifelong challenges and connect individuals to appropriate support and services.

Diagnostic Methods

Diagnosing autism spectrum disorder is not a simple process that can be completed with a single medical test. Instead, healthcare professionals use a combination of observations, developmental assessments, and structured evaluations to determine whether a person meets the criteria for autism. The diagnostic process usually involves multiple specialists and takes into account the individual's behavior across different settings and over time.

Developmental Monitoring and Screening

The first step in identifying autism often happens during routine well-child visits with a pediatrician or family doctor. Healthcare providers should track a child's development at every checkup, watching for milestones in social interaction, communication, movement, and behavior. This ongoing monitoring helps identify children who may need more in-depth evaluation.

Developmental screening is a more formal check to see if a child is learning basic skills when expected, or if there are delays. The American Academy of Pediatrics recommends that all children be screened specifically for autism at their 18-month and 24-month checkups, in addition to general developmental screening at regular intervals. These screening tools are questionnaires that parents complete or that healthcare providers use during the visit.

If a screening test suggests that a child may have autism, this does not mean the child definitely has the condition. It means that a more comprehensive evaluation is needed. Screening is meant to identify children who need further assessment, not to provide a diagnosis on its own.

Comprehensive Diagnostic Evaluation

When screening suggests autism, children should be referred to specialists who have expertise in diagnosing and treating autism spectrum disorder. This evaluation team may include a child psychiatrist, a child psychologist, a developmental pediatrician, a pediatric neurologist, or other professionals trained in developmental disorders. The comprehensive evaluation typically involves several components.

Specialists observe the child directly in structured and unstructured settings to see how they interact with others, play, communicate, and respond to different situations. They pay close attention to eye contact, response to their name, interest in sharing experiences with others, use of gestures and facial expressions, and any repetitive behaviors or intense interests. These observations provide crucial information about the child's social communication skills and behavioral patterns.

Parents and caregivers are asked detailed questions about the child's developmental history, including when they reached certain milestones, how they interact with family members and peers, their communication abilities, their daily routines and behaviors, and any concerns the family has noticed. This information helps specialists understand how the child has developed over time and how their behaviors appear in everyday life.

Standardized Assessment Tools

Specialists use specific, research-validated tools to assess a child's social communication and behavior systematically. These structured assessments present children with social situations or tasks and score their responses according to established criteria. The results help determine whether the child's development differs from what is typical for their age and whether they meet the criteria for autism spectrum disorder as defined in medical diagnostic manuals.

Testing for speech and language abilities is an important part of the evaluation, since communication challenges are a core feature of autism. A speech-language pathologist assesses both the child's ability to understand language and their ability to express themselves through words, gestures, or other means. Some children with autism have no spoken language, while others speak fluently but struggle to use language in social contexts.

Additional Medical and Genetic Testing

Because there is no medical test that can diagnose autism by itself, procedures like blood tests or brain scans are not used to confirm the diagnosis. However, healthcare providers may recommend certain medical tests to rule out other conditions that can cause similar symptoms or to identify co-occurring medical issues.

Hearing tests are important because hearing loss can affect communication and social interaction in ways that might resemble autism. Children should have their hearing checked to ensure that communication difficulties are not due to an inability to hear properly.

Genetic testing may be recommended for some children with autism. Researchers have identified certain genetic conditions, such as fragile X syndrome or Rett syndrome, that are associated with autism-like features. Identifying these conditions can provide families with information about inheritance patterns, possible medical complications, and specific treatment approaches. However, most cases of autism do not have a single identifiable genetic cause.

In some situations, doctors may order an electroencephalogram, which is a test that measures electrical activity in the brain. This test is not used to diagnose autism but may be performed if a child has symptoms that suggest seizures, since epilepsy occurs more frequently in people with autism than in the general population.

Distinguishing Autism From Other Conditions

Part of the diagnostic process involves making sure that the symptoms are not better explained by another condition. Children can have language delays, attention difficulties, or behavioral challenges for many reasons other than autism. Conditions like hearing impairment, intellectual disability, anxiety disorders, or attention-deficit/hyperactivity disorder can sometimes cause behaviors that resemble autism.

The diagnostic team carefully considers whether the child's social communication difficulties and repetitive behaviors are consistent with autism, rather than being secondary to another developmental or mental health condition. Sometimes a child may have autism along with other conditions, which is why a thorough evaluation by experienced professionals is essential.

Diagnostics for Clinical Trial Qualification

When individuals with autism are being considered for participation in clinical trials, researchers use specific diagnostic criteria and assessment tools to ensure that participants truly have autism spectrum disorder and meet the study's requirements. These standardized evaluations help researchers select appropriate participants and measure whether treatments or interventions being studied have meaningful effects.

Clinical trials typically require confirmation of an autism diagnosis using established diagnostic criteria from the Diagnostic and Statistical Manual of Mental Disorders. Researchers want to ensure that participants meet the core criteria for autism, which include persistent difficulties with social communication and social interaction, along with restricted, repetitive patterns of behavior, interests, or activities. These symptoms must cause significant challenges in daily functioning and must have been present since early childhood.

In addition to confirming the diagnosis, clinical trials often use standardized assessment tools to measure the severity of autism symptoms and associated behaviors. These measurements provide baseline information about each participant before the intervention begins, which researchers can compare to measurements taken during and after the study to determine whether the treatment had an effect. Different trials may focus on different aspects of autism, such as social communication skills, repetitive behaviors, anxiety, or irritability, and select assessment tools accordingly.

Age is another important factor in clinical trial eligibility. Some studies focus specifically on young children, adolescents, or adults, because autism affects people differently at various life stages. Researchers may exclude participants who are too young or too old for the specific intervention being tested. They also consider whether participants have other medical or psychiatric conditions that might interfere with the study or make it unsafe for them to participate.

Functional assessments help researchers understand how well potential participants can perform daily activities and participate in social, educational, or work settings. These evaluations may include measures of language ability, cognitive functioning, adaptive behavior skills, and overall level of independence. Clinical trials often have specific inclusion criteria based on these functional measures to ensure that the study includes participants who are most likely to benefit from the intervention being tested.

Some clinical trials may require genetic testing as part of their qualification process. This is particularly true for studies that are investigating treatments targeting specific genetic forms of autism or for research aimed at understanding the biological mechanisms underlying autism. Genetic testing can identify particular gene variants or chromosomal abnormalities that occur more frequently in individuals with autism.

Medical history and physical examination are standard parts of clinical trial screening. Researchers need to know about any other health conditions participants have, medications they are taking, and past treatments they have received. This information helps determine whether the experimental treatment might interact with existing medications or medical conditions, and whether it is safe for the person to participate in the study.

Did you know?

  1. There is no blood test, brain scan, or single medical procedure that can diagnose autism – the evaluation relies entirely on behavioral observation and developmental history, making it different from diagnosing most other medical conditions.
  2. Some children show all typical developmental milestones for their first 18-24 months and then suddenly begin losing language or social skills they had previously mastered, a pattern called regressive autism that challenges the idea that autism is always present from birth.
  3. More than one in 100 people are autistic, but many remain undiagnosed throughout their lives, particularly women and people from marginalized communities, because traditional diagnostic criteria were based primarily on how autism appears in white boys.

Questions people often ask

This guide is here to help you understand the condition. It does not replace a conversation with your doctor, who knows your situation best.

Clinical trials for Autism spectrum disorder

Recruiting trials first

See all 15 trials →
Quick filters

15 clinical trials in this condition

Countries:RomaniaRomania
  • Participants:0–17 years
  • Substances:Trospium Chloride
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company
Countries:BelgiumBelgium
  • Participants:0–17 years · Healthy volunteers
  • Substances:Oxytocin
  • Sponsor:UZ Leuven
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Oxytocin
  • Sponsor:UZ Leuven
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Arbaclofen
  • Sponsor:Fundacion Para La Investigacion Biomedica Del Hospital Gregorio Maranon
Countries:NorwayNorway
  • Participants:0–17 years · 18–64 years
  • Substances:Oxytocin
  • Sponsor:Oslo University Hospital HF
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Aripiprazole
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
See all 15 trials →filters applied: condition = Autism spectrum disorder

Related conditions in the same therapeutic area

Back to all diseases
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).